Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study.
Langslet G, Nyström T, Vistisen D, Carstensen B, Grip ET, Casajust P, Tskhvarashvili G, Hoti F, Klement R, Karlsdotter K, Tuovinen M, Ofstad AP, Lajer M, Shay C, Koeneman L, Farsani SF, Niskanen L, Halvorsen S. Langslet G, et al. Among authors: shay c. J Diabetes Res. 2024 Oct 12;2024:6142211. doi: 10.1155/2024/6142211. eCollection 2024. J Diabetes Res. 2024. PMID: 39430801 Free PMC article.
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
Edmonston D, Mulder H, Lydon E, Chiswell K, Lampron Z, Shay C, Marsolo K, Shah RC, Jones WS, Gordon H, Hwang W, Ayoub I, Ford D, Chamberlain A, Rao A, Fonseca V, Chang A, Ahmad F, Hung A, Hunt K, Butler J, Bosworth HB, Pagidipati N. Edmonston D, et al. Among authors: shay c. J Am Coll Cardiol. 2024 Aug 20;84(8):696-708. doi: 10.1016/j.jacc.2024.06.016. J Am Coll Cardiol. 2024. PMID: 39142723
Cell death shapes cancer immunity: spotlighting PANoptosis.
Gao L, Shay C, Teng Y. Gao L, et al. Among authors: shay c. J Exp Clin Cancer Res. 2024 Jun 15;43(1):168. doi: 10.1186/s13046-024-03089-6. J Exp Clin Cancer Res. 2024. PMID: 38877579 Free PMC article. Review.
Kidney and Cardiovascular Effectiveness of Empagliflozin Compared With Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes.
Edmonston D, Mulder H, Lydon E, Chiswell K, Lampron Z, Shay C, Marsolo K, Jones WS, Butler J, Shah RC, Chamberlain AM, Ford DE, Gordon HS, Hwang W, Chang A, Rao A, Bosworth HB, Pagidipati N. Edmonston D, et al. Among authors: shay c. Am J Cardiol. 2024 Jun 15;221:52-63. doi: 10.1016/j.amjcard.2024.04.011. Epub 2024 Apr 17. Am J Cardiol. 2024. PMID: 38641191
Cancer metabolism and carcinogenesis.
Yang J, Shay C, Saba NF, Teng Y. Yang J, et al. Among authors: shay c. Exp Hematol Oncol. 2024 Jan 29;13(1):10. doi: 10.1186/s40164-024-00482-x. Exp Hematol Oncol. 2024. PMID: 38287402 Free PMC article. Review.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Among authors: shay c. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
124 results